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This study was performed to elucidate whether xeroderma 
pigmentosum complementation group A (XPA) carrier has 
DNA repair abnormality against sun-exposure and ultravio-
let (UV)-mimetic chemical carcinogen 4-nitroquinoline 1-
oxide (4NQO). Here we report three sporadic cases of XP 
that were defined as group A by genetic complementation 
test as well as polymerase chain reaction (PCR) analysis to 
detect the point mutation in the responsible gene for XPA. 
DNA repair analyses in the skin fibroblasts revealed that the 
celts from the patients were much more sensitive to UV and 
4NQO and had extremely low UV-induced unscheduled 
X eroderma pigmencosum (XP) is a rare genetic disease clinically characterized by hypersunsensitivity, ab-normality in pigmentation, and predisposition to skin cancers in the hyper-sun-exposed area [1]. Cultured cells derived from XP patients excluding 
XP variants show hypersensitivity to the killing effect of UV irra-
diation, reduced DNA repair capacity, and high frequency of ultra-
violet (UV)-induced mutation. By cell fusion technique, there are at 
least seven genetic complementation groups, A through G, of im-
paired excision repair type and one excision repair- proficient var-
iant type. In Japan, patients are dominated by group A, the severest 
form of XP, and by the variant form [2]. Recently, a human gene 
responsible for complementing the defect in XP group A (XPA), 
XPAC (xeroderma pigmentosum A complementing) gene, was iso-
lated [3]. Most (approximately 85%) Japanese XPA patients are 
homozygous for the G~C transversion mutation of the XPAC 
gene at the splice acceptor site of intron 3. This point mutation 
creates a new cleavage site for the restriction endonuclease AlwNI. 
We can easily detect this base exchange by the AlwNI restriction 
enzyme fragment length polymorphism (RFLP) using the polymer-
ase chain reaction (PCR) technique, and identify XPA patients and 
XPA carriers [4] . 
Few precise clinical descriptions of parents of the XP patients 
(presumed carriers) and the characteristics of sun sensitivity and 
predisposition to skin cancers in XP carriers have been presented so 
far, because few carriers have been followed clinically for many 
years and cannot be accurately confirmed unti l recently. Cellular 
UV sensitivity of the carriers of XPA have been described to be 
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DNA synthesis (UDS) than control cells, whereas the cells 
from the carriers (heterozygotes ofXP) had sensitivity to UV 
and 4NQO and levels ofUV-induced UDS similar to normal 
cells. These results indicate that the obligate heterozygotes, 
despite having a mutated allele in XPA complementing gene 
demonstrated by PCR, have no DNA repair abnormality 
after UV irradiation and UV-mimetic 4NQO treatment. 
Our observations imply that XPA heterozygotes do not have 
higher risk of skin cancers than normal subjects based on their 
DNA repair abnormality.] Invest DermatoI100:69-72, 1993 
similar level to that of normal individuals [5,6]. However, in the 
parents of some of the De Sanctis Cachione syndrome patients, a 
significant reduction of the level of repair synthesis was found [7] 
and reports concerning their DNA repair capacity are conflicting. 
In these experiments, these parents have not actually been proved to 
be heterozygotes, though they are presumably heterozygote. It is 
important to know the peculiarity of the cells of the carriers for 
clinical counseling and cancer prevention. Previously we have re-
ported parents of one sporadic XPA patient had the mutated allele of 
XP AC gene in heterozygous state [8]. Here we analyzed two other 
sets ofxp A family, on the XPACgene genotype, detected the same 
mutation heterozygously in their parents, and confirmed that they 
are carriers. We aiso found that their cells had no DNA repair 
abnormality in the response to UV and a UV-mimetic chemical 
agent, 4-nitroquinoline-l-oxide (4NQO). 
PATIENTS AND THEIR PARENTS 
Case 1 (XP1EH) An 8-month - old Japanese boy had a history of 
severe sunburn with erythema and swelljng at 3 months. The 
freckles had increased on his face during the previous 4 months. His 
36-year - old parents (XP1EHF and XP1EHM) were consan-
guineous and had neither skin lesions nor sun sensitivity like their 
son. No relatives of his, including his three siblings, had any skin 
abnormality. 
Case 2 (XP6EH) A 2-year-old Japanese boy had repeated itchy 
erythematous lesions on his cheeks after sun bathing for more than 
20 min, yielding freckles. As yet he had no neurologic abnormality. 
His parents (XP6EHF and XP6EHM) were not consanguineous 
and did not have a history of sun sensitivity. 
Case 3 (XP22KY) A 3-year-old Japanese boy complained of a 
number of freckles on 1115 face. He had repeated histories of severe 
sunburning with blistering. No skin tumor had developed as yet (5 
years old). Fibroblast cells of the parents, who appeared to be normal 
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clinically without hypersunsensitivity and skin tumors, were not 
availab le. We previously reported the case [8). 
MATERIALS AND METHODS 
Cell Culture Cultured fibroblasts designated as XP1EH, 
XP6EH, and XP22KY derived from cases 1,2, and 3, respectively, 
were all established from the specimens of skin biopsies of the pa-
tients. Cells designated as XP1EHF, XP6EHF from fathers of the 
cases 1 and 2, respectively, and XP1EHM, XP6EHM from mothers 
of the cases 1 and 2, respectively, were also cultured from the skin 
biopsies. We used cultured fibroblasts, N-3, from a normal healthy 
volunteer as control [9]. Cells were maintained in Dulbecco's modi-
fied minimum essential medium (MEM) (Nissui, Tokyo, Japan) 
with 15% feta l bovine serum (HyClone, Logan, UT), at 37°C in a 
5% CO2 atmosphere. 
UVirradiation Three 10-W germicidal lampsemittingpredom-
inantly 254 nm (Toshiba GLlO) were used as the source of UV 
light. Fluence rates were determined by a UV radiometer (UVR-
254; Tokyo Kogaku Kikai KK, Tokyo, Japan). 
UV Sensitivity of Colony-Forming Ability Appropriate num-
ber of cells (500 - 2 X 104) were inoculated into 60-mm dishes and 
incubated for 18 h. After wash ing with phosphate-buffered saline, 
cells were exposed to UV and incubated for 1 - 2 weeks until colo-
nies (more than 50 cells) were formed. After fixation and staining, 
the number of colonies were counted. 
Treatment with 4NQO The stock solution was 0.01 M 4N QO 
(Wako pure chemical industries, LTD, Osaka, Japan) in ethanol. 
Treatment of 4NQO was carried out as previously described [10). 
Cells were plated into dishes, incubated for 18 h, then 4NQO solu-
tion (0-4 X 10-7 M) in MEM was added and incubated at 37°C for 
1 h. After the treatment, the cells were rinsed once in MEM and the 
culture medium was added for further incubation for 1-2 weeks to 
develop colonies. 
Meas~rement of UV-Induced Unscheduled DNA Synthesis 
Cells (5 X 104) were seeded on the glass cover slips in 35-mm 
dishes. After incubation for 18 h, cells were washed with phos-
phate-buffered saline and were irradiated by UV (0 and 30 J/m2), 
followed by incubation in the medium containing 10 ,uCi/ml of 
methyl-[3H]-thymidine (25 Ci/mmol, Amarsham, Buckingham-
shire, UK) for 3 h. After labeling, cells were fixed with Carnoy 
solution and washed with 5% trichloroacetic acid. Slides were 
dipped in nuclear track emulsion, NTB3 (Eastman Kodak, Roches-
ter, NY), for autoradiography. The number of grains per interphase 
nucleus was scored for 100 nuclei in each specimen. UDS was 
determined by the percent of net count when the net count of 
normal cells is 100%. Net count is determined by subtracting the 
mean grain count of the unirradiated cells from the mean grain 
count of the UV-irradiated cells. 
Extraction of DNA Genomic DNA was extracted from the cul-
tured fibroblasts as described by Maniatis et al [11 ]. Cells from a 
10-cm dish were harvested and suspended in digestion buffer with 
ribonuclease A for 3 h at room temperature and incubated with 100 
,ug/ml of proteinase K at 3rC overnight, followed by phenol-
chloroform (1: 1) extraction three times, and dialyzed against TE 
(10 mM Tris-CL, 1 mM ethylenediaminetetraacetic acid, pH 7.6) 
buffer. 
Amplification of Genomic XPAC Gene by Polymerase 
Chain Reaction Genomic DNA fragment including exon 4 
were amplified by PCR using the following/rimers containing 
an EcoRI restriction site at the 5' en: primer A, 5'-
GGGAATTCTTGCTGGGCTATTTGCAAAC-3' (intron 3) 
and primer B, 5' -GGGAA TTCGCCAAACCAA IT A IT AT-
GAC-3' (intron 4). Amplification with Taq DNA polymerase (Per-
kin-Eimer Cetus Instruments, Norwalk, CT) was carried out in an 
automatic thermocycler (PC-700, Astec, Fukuoka, Japan) as de-
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Table I. UV Sensitivity and UV-Induced DNA Repair Synthesis 
Number of Grains/Nucleus 
Cell Do (JIm2)' {Mean ± SD)b UDS' 
Strain (Mean ± SD) 30 J/m2 OJ/m2 Percent 
N-3 5.6 ± 0.4 45.3 ± 10.3 6.9 ± 2.3 100 
XPIEH 0.3 ± 0.1 5.4 ± 2.6 3.9 ± 1.9 4 
XPIEHF 5.9 ± 0.5 47.8 ± 12.4 6.6 ± 2.2 107 
XPIEHM 5.2 ± 0.7 48.5 ± 9.5 5.9 ± 2.5 111 
XP6EH 0.5 ± 0.1 5.2 ± 2.4 4.8 ± 1.6 1 
XP6EHF 5.8 ± 0.8 46.7 ± 11.4 7.9 ± 2.0 101 
XP6EHM 5.2 ± 0.2 51.2 ± 9.9 6.0 ± 2.2 118 
XP22KY 0.3 ± 0.1 6.6 ± 3.8 6.8 ± 4.2 0 
, Do is the dose required to yield 37% survival. Mean ± SO from three independent 
experiments. 
• Number of grains per interphase nucleus was scored for 100 nuclei in each sample. 
, Expressed as percentage of the UOS found in N-3 cells. 
scribed [8]. After the amplification, the DNA fragments were di-
gested with AlwNI and run in 5% polyacrylamide gel. 
RESULTS 
UV Sensitivity As shown in Table I and Fig 1, Do values of cells 
from the patients (XP1EH, XP6EH, and XP22KY) were much 
lower than normal cells (N-3) . In contrast, cells from the parents 
(XPIEHF, XPIEHM, XP6EHF, and XP6EHM) had similar Do 
values to control, showing that cells from the carriers ofXPA have 
the same sensitivity to UV at the fluence of 20 J/m2 or less. 
4NQO Sensitivity Cells of the parents of the patients 
(XPIEHF, XPIEHM, XP6EHF, XP6EHM) showed similar sensi-
tivity to 4NQO to normal cells (N-3). Cells of the XPA patients 
(XPIEH, XP6EH) were much more sensitive to 4NQO than N-3 
cells (Fig 2) . 
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Figure 1. UV sensitivity of colony-forming ability of cells. Cells of parents 
of the patients (XPIEHF,.; XPIEHM, 0; XP6EHF,~; XP6EHM, e) are 
as resistant as normal cells (N-3, 0). Cells from the patients (XP1EH, 0 ; 
XP6EH, 6.; XP22KY, .) are much more sensitive to UV than N-3. Each 
poi,,! is a mean value of three independent experiments. 
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Figure 2. 4NQO cytotoxicity of the cells. Symbols are the same as given in 
Fig 1. Each poillt is a mean value of three to five independent experiments. 
UV-Induced UDS Average net grain counts of UV-induced 
UDS in XP1EH, XP6EH, and XP22KY cells were 1.5, 0.4, and 
-0.2, respectively, and were less than 5% of 38.4 in normal N -3 
cells. Cells of the parents of the patients had almost the same level, 
100-120% of UDS, as N-3 cells (Table I). 
AlwNI Restriction Fragment Length Polymorphism (RFLP) 
in the Cells of the Patients and Their Parents To determine 
the mutation at the 3' end of intron 3 of XPAC, we examined the 
AlwNI RFLP in amplified DNA fragments of exon 3 including the 
flanking introns. DNA from the normal subject (N-3) gave a 328-
base-pair (bp) band, indicating that he had normal XPAC gene 
homozygously. In contrast, DNA of the patients gave two bands of 
244 bp and 84 bp because a new cleavage site for AlwNI was created 
in the amplified fragments. This observation indicates that these 
patients belonged to group A ofXP (Fig 3). This diagnosis was also 
confirmed by the genetic complementation test with cell fusion 
(data not shown). DNAs of their parents gave three bands (328 bp, 
244 bp, and 84 bp) by the RFLP analysis. This result showed that 
they had the same mutation of the XP AC gene as patients heterozy-
gously. and they were confirmed to be obligate heterozygotes of the 
mutant XPAC gene (Fig 3). The parents of XP22KY has been 
previously confirmed to have the same genotype as parents of 
XP1EH and XP6EH by using the PCR-RFLP technique [8]. 
DISCUSSION 
Three sporadic cases of the XP A were diagnosed clearly by the 
AlwNI RFLP in DNA using the PCR technique. The mutation site 
in the XPAC gene of these patients was all located at the same 
position and homozygous in the 3' splice acceptor site of intron 3, 
which was found in 85% of Japanese XPA patients [4]. We also 
found that this mutation in the XP AC gene in their parents was 
heterozygous and confirmed that they were the carriers of XP A 
despite the fact that the patients all seemed to be sporadic cases in 
clinical views. We could identify phenotypically normal XPA 
carriers by the PCR-RFLP in genera l population. 
The frequency of XP patients in newborn babies in Japanese 
people is approximately 1 in 100,000 [2]. According to the Hardy-
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Weinberg law [12], the frequency ofXPA carriers is assumed to be 
approximately 1 in 250 in Japanese people because 40% of the 
Japanese XP patients belong to group A. All three pedigrees re-
ported here were not related and no other patients were recorded in 
these families. The mutated XPAC gene must have been transmit-
ted heterozygously and independently in each pedigree. 
Few precise clinical descriptions of the XP carriers, including the 
sun sensitivity, skin abnormality like freckles, and predisposition to 
skin cancer, have been reported so far. The characteristics of the 
cells of XP heterozygotes are considered to be controversial and 
have not been well understood. Using the UV-induced incorpora-
tion of 5-bromodeoxyuridine into nonreplicated DNA, Cleaver 
found about 45% normal repair replication in two XP heterozy-
gotes, about 80% normal in another, and 100% in another [13]. 
Kleijer et al [7] demonstrated that DNA repair capacity was reduced 
at the UV doses of 25 - 100 J / m2 in two of seven presumed XP A 
heterozygotes. Day [6] speculated at a fluence of 7 J/m2, which 
corresponds to 5 X 105 dimers/cell, the repair enzyme in the cell 
was consumed completely and cells became sensitive to UV at 
higher doses. In contrast, Regan et al [5] reported that a heterozy-
gous XPA cell strain had normal DNA repair ability at a dose of20 
J/m2. The reasons for these discrepancies have not been clearly 
understood. 
In this study, heterozygosity was confirmed by the presence of 
the new AlwNI cleavage site. XPA patients with homozygosity in 
the mutation yielding the AlwNI site are the most severe in symp-
toms among various genetic groups of XP. There were no clear 
clinical manifestations of any skin symptoms in all six confirmed 
heterozygotes. Also, no detectable repair defects were found in four 
of them, at least for the excision-resynthesis type of DNA repair. 
This is the first demonstration of the absence of DNA repair defi-
ciency in the confirmed obligate heterozygotes of XP. Undetected 
defects in DNA repair other than the excision-resynthesis type can-
not be excluded, but so far such defects have not been suspected in 
the cells cultured from any XPA patients. Swift and Chase reported 
the excess non-melanoma skin cancers among blood relatives in 
31 XP families and suggested the hypothesis that heterozygous 
carriers of an XP gene have a greater risk for skin cancer than do 
non-carriers [14]. The cause of the high incidence of skin cancer in 
XP heterozygotes they reported cannot be explained from our re-
su lts. One possibility is that the patients in their study do not have 
the mutation yielding the AlwNI site, but might have other muta-
tion(s) that can affect those in a heterozygous state. As far as we 
know, no parents ofXP patients are reported to have skin cancers, 
and incidence of skin cancer in the parents ofxp patients is consider-
ably low. However, it is possible that the Japanese XPA heterozy-
gotes in this study have a much higher risk of developing skin 
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Figure 3. AlwNI RFLP analysis of the amplified DNAs. Heterozygotes in 
{atle 2 (XPIEHF), {atle 3 (XPIEHM), {aile 6 (XP6EHF). and {atle 7 
(XP6EHM) show three fragments (328, 244, and 84 base pairs). whereas 
XPA homozygotes in fatl es 4 and 8 (XPIEH and XP6EH, respectively) give 
two bands (244 and 88 base pairs) . DNA from normal cells in {Otl es 1 and 5 
(N-3) give one band (328 base pairs). M, marker lane containing HinelI 
digest of oX174 DNA. Similar results of AlwNI RFLP in XP22KY and his 
parents were presented previously [8]. 
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cancer than other Japanese individuals yet, due to chance, this has 
not yet happened. 
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ANNOUNCEMENT 
Applications are now available for 1994 for the four categories of research awards sponsored by 
the Dermatology Foundation according to President Howard V. Dubin, M.D. 
Leader Society Clinical Career Development Award: The Clinical Career Development 
Award supports young, clinically-oriented academic investigators. Purpose: to enhance the 
academic career of a clinician-scientist who is a faculty member in a department or division of 
dermatology and who has completed initial training (2-3 year research fellowship or equiva-
lent experience) in relevant research and is devoted to pursuing a clinical investigation intended 
to improve clinical dermatology. The primary criteria for selection are the quality of dermatol-
ogy. Stipend: $40,000 per year, may be renewed for two additional years . 
Career Development Awards in Skin Research: Designed to assist in the transition from 
fellowship to established investigator. Junior investigators in the early stages of their academic 
careers who are faculty members in a department or division of dermatology, and have com-
pleted initial training (a 2-3 year research fellowship or equivalent experience) in biomedical 
research are encouraged to apply. Stipend: $40,000 per year. 
Fellowships: For post-doctoral fellows to support research training in dermatology and cutane-
ous biology. One fellowship is also available in the area of skin photobiology. Stipend: $25 ,000 
per year. 
Grants: Awarded to initiate research projects in dermatology and cutaneous biology. Special 
grants are also available for research in skin cancer, dermatologic surgery and oncology, and 
epidermolysis bullosa. Stripend: $ 10,000 for one year. 
The deadline for applications, for all four levels of research, including all supporting materi-
als is August 1, 1993. Awards will be presented at the 29th Annual Meeting of the Dermatol-
ogy Foundation, during the first part of December, in Washington D.C. For details and 
application materials, please contact the Medical and Scientific Committee, Dermatology 
Foundation, 1560 Sherman Avenue, Ste. 302, Evanston, IL 60201. (708) 328-2256; Fax, 
(708) 328-0509. 
